Diana H Kim1,2, Feng-Ju Chien3, Howard J Eisen4. 1. Drexel University College of Medicine, 2900 W Queen Lane, Philadelphia, PA, 19129, USA. dhk45@drexel.edu. 2. Drexel University College of Medicine, 2900 W. Queen Lane, Philadelphia, PA, 19145, USA. dhk45@drexel.edu. 3. Villanova University, 800 Lancaster Ave, Villanova, PA, 19085, USA. 4. Drexel University College of Medicine, 2900 W Queen Lane, Philadelphia, PA, 19129, USA.
Abstract
PURPOSE OF REVIEW: This review aims to summarize the growing body of literature of HF with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) with a focus on recent pharmacologics. RECENT FINDINGS: HFrEF continues to be more widely investigated than HFpEF. Ivabradine and combinatorial treatment with sacubitril and valsartan are promising newly approved therapies. Other experimental therapies have emerged, which include Serelaxin, Empagliflozin, Neuregulin, and Omecamtive mecarbil, among others. These drugs need to continue to be investigated for safety and efficacy. We predict ivabradine and combinatorial treatment with sacubitril-valsartan to develop as a widespread therapy. New therapies should be aimed at treating HFpEF or target the cardiomyocyte itself.
PURPOSE OF REVIEW: This review aims to summarize the growing body of literature of HF with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) with a focus on recent pharmacologics. RECENT FINDINGS: HFrEF continues to be more widely investigated than HFpEF. Ivabradine and combinatorial treatment with sacubitril and valsartan are promising newly approved therapies. Other experimental therapies have emerged, which include Serelaxin, Empagliflozin, Neuregulin, and Omecamtive mecarbil, among others. These drugs need to continue to be investigated for safety and efficacy. We predict ivabradine and combinatorial treatment with sacubitril-valsartan to develop as a widespread therapy. New therapies should be aimed at treating HFpEF or target the cardiomyocyte itself.
Authors: Viviane M Conraads; Marco Metra; Otto Kamp; Gilles W De Keulenaer; Burkert Pieske; José Zamorano; Panos E Vardas; Michael Böhm; Livio Dei Cas Journal: Eur J Heart Fail Date: 2011-12-06 Impact factor: 15.534
Authors: Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt Journal: N Engl J Med Date: 2010-11-14 Impact factor: 91.245
Authors: John R Teerlink; G Michael Felker; John J V McMurray; Piotr Ponikowski; Marco Metra; Gerasimos S Filippatos; Justin A Ezekowitz; Kenneth Dickstein; John G F Cleland; Jae B Kim; Lei Lei; Beat Knusel; Andrew A Wolff; Fady I Malik; Scott M Wasserman Journal: J Am Coll Cardiol Date: 2016-03-29 Impact factor: 24.094
Authors: John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana R Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas M Severin; Marco Metra Journal: Lancet Date: 2012-11-07 Impact factor: 79.321
Authors: Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: Mihai Gheorghiade; John E A Blair; Gerasimos S Filippatos; Cezar Macarie; Witold Ruzyllo; Jerzy Korewicki; Serban I Bubenek-Turconi; Maurizio Ceracchi; Maria Bianchetti; Paolo Carminati; Dimitrios Kremastinos; Giovanni Valentini; Hani N Sabbah Journal: J Am Coll Cardiol Date: 2008-04-09 Impact factor: 24.094
Authors: John R Teerlink; Adriaan A Voors; Piotr Ponikowski; Peter S Pang; Barry H Greenberg; Gerasimos Filippatos; G Michael Felker; Beth A Davison; Gad Cotter; Claudio Gimpelewicz; Leandro Boer-Martins; Margaret Wernsing; Tsushung A Hua; Thomas Severin; Marco Metra Journal: Eur J Heart Fail Date: 2017-04-28 Impact factor: 15.534